Market Overview

Biogen Ticks Up Following EU Marketing Authorization Of Benepali

Share:

Shares of Biogen Inc (NASDAQ: BIIB) were trading higher by 2 percent at $279.00 early Tuesday morning after the company announced that the European Union has granted marketing authorization for its BENEPALI.

BENEPALI is an etanercept biosimilar referencing Enbrel and is the first etanercept biosimilar referencing Enbrel to be approved in the EU. Biogen has been working with Samsung BioLogics to create a product that is used for the treatment of adults with moderate to severe rheumatoid arthritis (RA), psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque psoriasis.

Biogen noted that BENEPALI will be available for patients in the coming weeks.

"The approval of BENEPALI is a significant step forward for patients and physicians, and an important milestone for Biogen as we bring to market the first product from our biosimilar pipeline," said Alpna Seth, Ph. D., Senior Vice President and Global Head of the Biosimilars Business Unit at Biogen. "As a biotechnology pioneer, Biogen is proud to translate our heritage and expertise in biologics to biosimilars. BENEPALI, as the first etanercept biosimilar referencing Enbrel approved in the EU, can help expand access to treatment options for people affected by chronic inflammatory conditions."

Posted-In: Alpna Seth Arthiritis BENEPALI Biogen European Union Marketing AuthorixationNews Health Care General

 

Related Articles (BIIB)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

SunTrust Reiterates 'Buy The Dip' In Fitbit

Google Prepares For A Virtual Reality Explosion